Search Results
–255. EMEA: Mabthera: Alkalmazási előirat. EMEA, 2006. Cohen, S. B., Emery, P., Greenwald, M. W. és mtsai: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a
Abulayha, A. M., Tabal, S. A., Shawesh, E. I., et al.: Depletion of peripheral blood B cells with rituximab and phenotype characterization of the recovering population in a patient with follicular
Diffúz nagy B-sejtes limfóma autológ transzplantációt követő relapszusának sikeres kezelése rituximab-bendamustinvenetoclax kombinációs kezeléssel
Successful treatment of relapsed diffuse large B-cell lymphoma after autologous transplantation with rituximab-bendamustine-venetoclax combination therapy
. Blood Adv. 2020; 4: 4669–4678. 2 Morschhauser F, Flinn IW, Advani R, et al.: Polatuzumabvedotin or pinatuzumabvedotin plus rituximab in patients with relapsed or
fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol., 2009, 27 , 498–503. Land S. R
Coiffier, B., Lepage, E., Briere, J. és mtsai: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med., 2002, 346 , 235–242. Briere J
Coiffier, B., Lepage, E., Briere, J. és mtsai: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med., 2002, 346 , 235–242. Briere J
Óriássejtes hepatitis és autoimmun haemolyticus anaemia társulása kisdedkorban
Association of giant cell hepatitis and autoimmune hemolytic anemia in infancy
autoimmune hemolytic anemia using rituximab. Pediatr Gastroenterol Hepatol Nutr. 2020; 23: 180–187. 4 Gorelik M, Debski R, Frangoul H. Autoimmune hemolytic
Abstract
Rituximab was successively labeled with [67Ga]-gallium chloride after residulation with freshly prepared cyclic DTPA-dianhydride. The best results of the conjugation were obtained by the addition of 1 ml of a rituximab pharmaceutical solution (5 mg/ml, in phosphate buffer, pH 8) to a glass tube pre-coated with DTPA-dianhydride (0.01 mg) at 25 °C with continuous mild stirring for 30 minutes. Radio thin-layer chromatography showed an overall radiochemical purity of 96–99% at optimized conditions (specific activity = 300–500 MBq/mg, labeling efficiency 77%). The final isotonic 67Ga-DTPA-rituximab complex was checked by gel electrophoresis for radiolysis control. Radio-TLC was performed to ensure the formation of only one species, followed by filtration through a 0.22 μm filter. Preliminary in vivo studies in normal rat model was performed to determine the biodistribution of the radioimmunoconjugate up to 6 hours.
Schulz, H., Bohlius, J. F., Trelle, S. és mtsai: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J. Natl. Cancer. Inst., 2007, 99 , 706
.: Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br. J. Haematol., 2009, 147 , 677–680. Heffner L. T
